Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATHE 
Alterity Therapeutics Ltd (ATHE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: ATHE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.46% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.31M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 3 | Beta 0.72 | 52 Weeks Range 1.00 - 5.87 | Updated Date 07/1/2025 |
52 Weeks Range 1.00 - 5.87 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -469.68% |
Management Effectiveness
Return on Assets (TTM) -78.37% | Return on Equity (TTM) -155.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 55097901 | Price to Sales(TTM) 16.46 |
Enterprise Value 55097901 | Price to Sales(TTM) 16.46 | ||
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 14803400 | Shares Floating 4310429916 |
Shares Outstanding 14803400 | Shares Floating 4310429916 | ||
Percent Insiders - | Percent Institutions 1.6 |
Analyst Ratings
Rating 2 | Target Price 11 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alterity Therapeutics Ltd
Company Overview
History and Background
Alterity Therapeutics Ltd, formerly Prana Biotechnology, focuses on developing treatments for neurodegenerative diseases. Founded to commercialize research, it has shifted focus to iron-related neurodegeneration.
Core Business Areas
- Drug Development: Developing novel therapies for neurodegenerative diseases, specifically focusing on iron chaperones and their role in disease progression.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates, such as ATH434 for Multiple System Atrophy (MSA).
Leadership and Structure
The leadership team consists of a CEO (David Stamler, MD), a Chief Medical Officer, and a board of directors. The organizational structure is typical of a biotech company, with departments for research, clinical development, and administration.
Top Products and Market Share
Key Offerings
- ATH434: ATH434 is Alterity's lead drug candidate, an iron chaperone being developed for Multiple System Atrophy (MSA). There is no market share data available, as it's in clinical development. Competitors include companies developing symptomatic treatments and disease-modifying therapies for MSA, such as those working on alpha-synuclein aggregation.
Market Dynamics
Industry Overview
The industry is characterized by high unmet need for effective treatments for neurodegenerative diseases. Significant investment in research and development drives innovation in this field.
Positioning
Alterity is positioned as a company focused on addressing iron dysregulation in neurodegenerative diseases, offering a potentially disease-modifying approach. Its competitive advantage lies in its iron chaperone technology.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease treatments is estimated to be billions of dollars. Alterity is positioned to capture a share of this market if ATH434 proves successful.
Upturn SWOT Analysis
Strengths
- Novel iron chaperone technology
- Focus on disease-modifying therapies
- Lead candidate in clinical development for MSA
Weaknesses
- Single lead product
- High dependence on clinical trial success
- Limited financial resources
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to other neurodegenerative diseases
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- There are no key competitors that have the same drug target. Other companies with neurodegenerative disease programs: BIIB
- SNY
- ABBV
Competitive Landscape
Alterity has a novel approach, but it is a small player compared to larger pharmaceutical companies developing treatments for neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been dependent on clinical trial progression and related fund raising events.
Future Projections: Future growth depends on the success of ATH434 and the ability to secure partnerships or further funding.
Recent Initiatives: Recent initiatives include advancing ATH434 through clinical trials and exploring other potential applications of its technology.
Summary
Alterity Therapeutics is a development-stage biotech company with a focus on iron chaperones for neurodegenerative diseases. Its success hinges on the clinical development of ATH434, its lead product. While it has a novel approach, it faces risks associated with clinical trials and competition from larger pharmaceutical companies. Funding and partnerships are critical for its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial registries
Disclaimers:
This analysis is based on available information and is not financial advice. Investment in biotechnology companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alterity Therapeutics Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2002-09-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://alteritytherapeutics.com |
Full time employees 10 | Website https://alteritytherapeutics.com | ||
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.